Tempest Therapeutics Target of Unusually High Options Trading (NASDAQ:TPST)

Tempest Therapeutics, Inc. (NASDAQ:TPST) saw unusually large options trading activity on Wednesday. Investors bought 2,888 call options on the stock. This is an increase of 1,069% compared to the average volume of 247 call options.

Tempest Therapeutics Trading Up 3.6 %

TPST opened at $1.15 on Friday. Tempest Therapeutics has a 1-year low of $0.92 and a 1-year high of $7.32. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio of 0.12. The company has a market cap of $25.55 million, a P/E ratio of -0.67 and a beta of -1.86. The company has a fifty day moving average price of $1.31 and a two-hundred day moving average price of $2.33.

Tempest Therapeutics (NASDAQ:TPST) last posted its earnings results on Thursday, August 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. Analysts predict that Tempest Therapeutics will post -1.43 EPS for the current fiscal year.

Insider Transactions at Tempest Therapeutics

In related news, major shareholder Versant Venture Capital Vi, L. sold 387,999 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $1.10, for a total transaction of $426,798.90. Following the sale, the insider now owns 209,941 shares in the company, valued at approximately $230,935.10. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 3.27% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 25,084 shares of the company’s stock, valued at approximately $55,000. Dimensional Fund Advisors LP owned about 0.11% of Tempest Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 22.52% of the company’s stock.

Analyst Upgrades and Downgrades

TPST has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, October 10th. Piper Sandler reissued an “overweight” rating and set a $8.00 target price on shares of Tempest Therapeutics in a research note on Friday, June 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $20.75.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.